BR112013002250A2 - composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. - Google Patents

composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.

Info

Publication number
BR112013002250A2
BR112013002250A2 BR112013002250A BR112013002250A BR112013002250A2 BR 112013002250 A2 BR112013002250 A2 BR 112013002250A2 BR 112013002250 A BR112013002250 A BR 112013002250A BR 112013002250 A BR112013002250 A BR 112013002250A BR 112013002250 A2 BR112013002250 A2 BR 112013002250A2
Authority
BR
Brazil
Prior art keywords
compound
schisophrenia
depression
disease
attention deficit
Prior art date
Application number
BR112013002250A
Other languages
English (en)
Other versions
BR112013002250B1 (pt
Inventor
Eiji Honda
Masakuni Kori
Masashi Toyofuku
Michiyo Mochizuki
Osamu Ujikawa
Shinji Nakamura
Toshihiro Imaeda
Yasutomi Asano
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BR112013002250A2 publication Critical patent/BR112013002250A2/pt
Publication of BR112013002250B1 publication Critical patent/BR112013002250B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal dealzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto - é fornecido um composto representado pela fórmula (i): em que cada símbolo é como definido no relatório descritivo, ou um sal deste, que tem uma ação potenciadora do receptor de ampa (ácido <244>-amido-3hidróxi-5-metil-4-isoxazolpropiônico). o composto da presente invenção é útil como um medicamento profilático ou terapêutico para a depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção (adhd) e os semelhantes.
BR112013002250-7A 2010-08-10 2011-08-09 composto, composição farmacêutica, e, uso de um composto BR112013002250B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010179577 2010-08-10
JP2010-179577 2010-08-10
PCT/JP2011/068497 WO2012020848A1 (en) 2010-08-10 2011-08-09 Heterocyclic compound and use thereof

Publications (2)

Publication Number Publication Date
BR112013002250A2 true BR112013002250A2 (pt) 2016-05-24
BR112013002250B1 BR112013002250B1 (pt) 2020-10-27

Family

ID=44534564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002250-7A BR112013002250B1 (pt) 2010-08-10 2011-08-09 composto, composição farmacêutica, e, uso de um composto

Country Status (38)

Country Link
US (10) US9150591B2 (pt)
EP (1) EP2603513B1 (pt)
JP (2) JP5788496B2 (pt)
KR (1) KR101852215B1 (pt)
CN (2) CN103180326B (pt)
AR (1) AR082618A1 (pt)
AU (1) AU2011290126B2 (pt)
BR (1) BR112013002250B1 (pt)
CA (1) CA2807460C (pt)
CL (1) CL2013000380A1 (pt)
CO (1) CO6680700A2 (pt)
CR (1) CR20130066A (pt)
CY (1) CY1123507T1 (pt)
DK (1) DK2603513T3 (pt)
DO (1) DOP2013000030A (pt)
EA (1) EA022078B1 (pt)
EC (1) ECSP13012478A (pt)
ES (1) ES2793723T3 (pt)
GE (1) GEP20156216B (pt)
HR (1) HRP20200844T1 (pt)
HU (1) HUE049460T2 (pt)
IL (1) IL224452A (pt)
LT (1) LT2603513T (pt)
MA (1) MA34509B1 (pt)
MX (1) MX349470B (pt)
MY (1) MY165908A (pt)
NZ (1) NZ607593A (pt)
PE (1) PE20131116A1 (pt)
PL (1) PL2603513T3 (pt)
PT (1) PT2603513T (pt)
RS (1) RS60311B1 (pt)
SG (1) SG187656A1 (pt)
SI (1) SI2603513T1 (pt)
TW (1) TWI504604B (pt)
UA (1) UA111594C2 (pt)
UY (1) UY33551A (pt)
WO (1) WO2012020848A1 (pt)
ZA (1) ZA201301120B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082618A1 (es) * 2010-08-10 2012-12-19 Takeda Pharmaceutical Derivados de tiadiazina, composiciones farmaceuticas y usos
WO2012137982A2 (en) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2013118845A1 (ja) * 2012-02-08 2013-08-15 武田薬品工業株式会社 複素環化合物およびその用途
CA2915405A1 (en) * 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
CN105324376B (zh) 2013-06-27 2017-06-23 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
SI3077374T1 (sl) 2013-12-03 2020-07-31 Fmc Corporation Pirolidinoni kot herbicidi
AU2015284280C1 (en) 2014-07-02 2020-02-13 Fmc Corporation Piperidinone herbicides
BR112017009701B1 (pt) 2014-12-08 2021-09-08 Fmc Corporation Composto e métodos de preparação de compostos
BR112017017945B1 (pt) 2015-04-10 2021-06-08 Fmc Corporation composto, composições herbicidas, mistura herbicida e método de controle do crescimento de vegetação indesejada
WO2016176082A1 (en) 2015-04-27 2016-11-03 E I Du Pont De Nemours And Company Butyrolactones as herbicides
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
WO2016176460A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
CN107592862B (zh) 2015-05-12 2021-06-15 Fmc公司 作为除草剂的芳基取代的双环化合物
US10906873B2 (en) 2015-05-29 2021-02-02 Fmc Corporation Substituted cyclic amides as herbicides
EP3303321A1 (en) 2015-06-02 2018-04-11 E. I. du Pont de Nemours and Company Substituted cyclic amides and their use as herbicides
AU2016303209B2 (en) 2015-07-31 2021-04-01 Fmc Corporation Cyclic N-carboxamide compounds useful as herbicides
SI3331892T1 (sl) * 2015-08-06 2019-10-30 Hoffmann La Roche Postopki za pripravo derivatov gaINAc kisline
TW201713774A (zh) 2015-08-06 2017-04-16 Kohjin Life Sciences Co Ltd 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
US20170181292A1 (en) * 2015-12-16 2017-06-22 Rohm And Haas Electronic Materials Llc Method for forming organic coating on nickel surface
CN105669731B (zh) * 2016-01-10 2017-06-30 沧州普瑞东方科技有限公司 一种4‑(4‑烷基环己氧基)苯硼酸的合成方法
BR112019012910B1 (pt) 2016-12-21 2023-10-17 Fmc Corporation Composto, composição herbicida, mistura herbicida e método para controlar o crescimento de vegetação indesejável
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物
BR112019019605B1 (pt) 2017-03-21 2023-03-07 Fmc Corporation Compostos e processo para preparar um composto de fórmula ii-a
CA3057300A1 (en) 2017-03-21 2018-09-27 Fmc Corporation Herbicidal mixture, composition and method
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
EP3693368B1 (en) * 2017-10-06 2023-12-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3693360B1 (en) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EP4149478A1 (en) 2020-05-15 2023-03-22 Takeda Pharmaceutical Company Limited Treatment for depression

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0437742Y2 (pt) 1986-10-22 1992-09-04
JPH0285851A (ja) * 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
JPH037742A (ja) 1989-06-05 1991-01-14 Toyo Tire & Rubber Co Ltd ラバーチエーン用ゴム組成物
JP2874960B2 (ja) * 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
JP2003526341A (ja) 1999-11-04 2003-09-09 コロラド ステート ユニバーシティー リサーチ ファウンデーション 昆虫を誘引するための装置および方法
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2005508352A (ja) * 2001-10-10 2005-03-31 ニューロサーチ、アクティーゼルスカブ 新規ベンゾチアジン誘導体、その製造方法及びその使用方法
FR2833955B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) * 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2007100527A4 (en) 2006-06-23 2007-08-23 Nufarm Australia Limited Phenoxy alkanoate herbicidal composition and method of preparation and use
EP2102153A1 (en) * 2006-12-11 2009-09-23 Eli Lilly &amp; Company Ampa receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
JP2011503002A (ja) * 2007-11-05 2011-01-27 シェーリング コーポレイション γセクレターゼ調節剤
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
JP2009248543A (ja) * 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
AU2009313527A1 (en) 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (ja) 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
AR082618A1 (es) * 2010-08-10 2012-12-19 Takeda Pharmaceutical Derivados de tiadiazina, composiciones farmaceuticas y usos

Also Published As

Publication number Publication date
ES2793723T3 (es) 2020-11-16
UY33551A (es) 2012-03-30
HUE049460T2 (hu) 2020-09-28
SG187656A1 (en) 2013-03-28
US11279713B2 (en) 2022-03-22
US20180162875A1 (en) 2018-06-14
US20130190291A1 (en) 2013-07-25
US9884875B2 (en) 2018-02-06
JP2016006080A (ja) 2016-01-14
TWI504604B (zh) 2015-10-21
US20150353578A1 (en) 2015-12-10
TW201217386A (en) 2012-05-01
EP2603513A1 (en) 2013-06-19
US8916551B2 (en) 2014-12-23
CL2013000380A1 (es) 2013-05-31
GEP20156216B (en) 2015-01-12
US20140080817A1 (en) 2014-03-20
AU2011290126B2 (en) 2016-01-07
EA022078B1 (ru) 2015-10-30
SI2603513T1 (sl) 2020-07-31
UA111594C2 (uk) 2016-05-25
RS60311B1 (sr) 2020-07-31
WO2012020848A1 (en) 2012-02-16
CY1123507T1 (el) 2022-03-24
US9150591B2 (en) 2015-10-06
KR101852215B1 (ko) 2018-04-25
US9499568B2 (en) 2016-11-22
IL224452A (en) 2017-11-30
CN103180326A (zh) 2013-06-26
NZ607593A (en) 2015-01-30
AU2011290126A1 (en) 2013-03-07
CN103180326B (zh) 2015-06-10
DK2603513T3 (da) 2020-06-15
ECSP13012478A (es) 2013-04-30
MA34509B1 (fr) 2013-09-02
US8575154B2 (en) 2013-11-05
AR082618A1 (es) 2012-12-19
MX349470B (es) 2017-07-31
WO2012020848A8 (en) 2012-09-27
CN104926837A (zh) 2015-09-23
BR112013002250B1 (pt) 2020-10-27
MY165908A (en) 2018-05-18
MX2013001614A (es) 2013-07-05
PE20131116A1 (es) 2013-10-24
HRP20200844T1 (hr) 2020-08-21
PL2603513T3 (pl) 2020-07-27
US20150073137A1 (en) 2015-03-12
LT2603513T (lt) 2020-05-25
JP6113789B2 (ja) 2017-04-12
EA201390222A1 (ru) 2013-08-30
US20190263832A1 (en) 2019-08-29
CA2807460C (en) 2018-09-18
US20200317692A1 (en) 2020-10-08
DOP2013000030A (es) 2013-03-15
US20170022222A1 (en) 2017-01-26
US20120077799A1 (en) 2012-03-29
PT2603513T (pt) 2020-06-08
CA2807460A1 (en) 2012-02-16
ZA201301120B (en) 2014-04-30
US10654874B2 (en) 2020-05-19
US8778934B2 (en) 2014-07-15
KR20130138738A (ko) 2013-12-19
CR20130066A (es) 2013-05-03
JP2013535408A (ja) 2013-09-12
CO6680700A2 (es) 2013-05-31
JP5788496B2 (ja) 2015-09-30
EP2603513B1 (en) 2020-03-11
US20130184266A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
BR112013002250A2 (pt) composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
BR112014025711A8 (pt) composto, medicamento, e, uso de um composto
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112016024472A8 (pt) composto, medicamento, e, uso de um composto
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112012020311A2 (pt) &#34;compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto.&#34;
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014026703A2 (pt) inibidores de dna-pk
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112014009866A2 (pt) formulações de anticorpos e métodos
BRPI1014802B8 (pt) profármacos de triptolida.
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
BR112015030431A2 (pt) formulação de liberação modificada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/08/2011, OBSERVADAS AS CONDICOES LEGAIS.